AAPG ASCENTAGE PHARMA GROUP INTERNATIONAL
Price Chart
Executive Summary
Ascentage Pharma presented positive clinical data for three key drug candidates at ASCO 2026, including first pediatric data for MDM2-p53 inhibitor alrizomadlin, updated olverembatinib results in CML-CP, and olverembatinib + blinatumomab in advanced Ph+ leukemias. The data are encouraging but preliminary, with no immediate financial impact.
Actionable Insight
The data are positive but early-stage; watch for upcoming regulatory milestones (FDA filings for olverembatinib, Takeda option decision) and further readouts. Near-term stock price movement likely limited given historical weak reaction to pipeline updates.
Key Facts
- First dataset for alrizomadlin (APG-115) in pediatric solid tumors: ORR 23.5% in combination arm, 1 CR in monotherapy.
- Olverembatinib as second-line CML-CP: at cycle 24, CCyR 91.3%, MMR 60.9%, deepening over time.
- Olverembatinib + blinatumomab in CML-LBP/Ph+ BCP-ALL: 91% CR/CRi, 67% BCR::ABL1 negativity, 80% MRD negativity.
- All three studies were selected as rapid oral presentations at ASCO 2026; alrizomadlin included in China's SPARK Plan for pediatric solid tumors.
- No financial or revenue data included in the filing; all drugs remain investigational in the US.
Financial Impact
No financial figures provided; clinical data may support future regulatory filings and Takeda option exercise, but no near-term revenue impact.
Risk Factors
- Clinical data are preliminary and from small sample sizes; larger confirmatory trials needed.
- All candidates remain unapproved by the US FDA; regulatory risk persists.
- Historical stock price reactions to similar announcements have been negative on average.
Market Snapshot
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-063156 |
| Document: ea029289901ex99-2.htm | 0001213900-26-063156 |
| Document: ea029289901ex99-3.htm | 0001213900-26-063156 |
| Document: ea0292899-6k_ascentage.htm | 0001213900-26-063156 |
| Document: 0001213900-26-063156-index-headers.html | 0001213900-26-063156 |
| Document: 0001213900-26-063156-index.html | 0001213900-26-063156 |
| Document: 0001213900-26-063156.txt | 0001213900-26-063156 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 14, 2026
today
|
Press Release
| — | awaiting T+5 | — | — |
|
Jun 1, 2026
13d ago
|
6-K
| $19.08 $17.20 | ▼ −9.85% | ▼ −7.10% | $17.60 (−7.76%) |
|
May 28, 2026
17d ago
|
6-K
| $20.01 $17.20 | ▼ −14.04% | ▼ −11.52% | $17.60 (−12.04%) |
|
May 28, 2026
17d ago
|
6-K
| $19.88 $17.87 | ▼ −10.11% | ▼ −10.06% | $17.60 (−11.47%) |
|
May 22, 2026
23d ago
|
6-K
| $21.01 $19.08 | ▼ −9.19% | ▼ −10.86% | $17.60 (−16.23%) |
|
May 22, 2026
24d ago
|
Press Release
| $21.01 $19.08 | ▼ −9.19% | ▼ −10.84% | $17.60 (−16.23%) |
|
May 13, 2026
4w ago
|
6-K
| $21.38 $18.99 | ▼ −11.18% | ▼ −10.02% | $17.60 (−17.68%) |
|
May 12, 2026
4w ago
|
6-K
| $21.16 $18.56 | ▼ −12.29% | ▼ −12.37% | $17.60 (−16.82%) |
|
Apr 22, 2026
7w ago
|
6-K
| $25.13 $22.75 | ▼ −9.47% | ▼ −9.53% | $17.60 (−29.96%) |
|
Apr 22, 2026
7w ago
|
Press Release
| $25.13 $22.75 | ▼ −9.47% | ▼ −9.53% | $17.60 (−29.96%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access